NSAID-Induced Small Intestinal Damage - Roles of Various Pathogenic Factors
被引:48
作者:
论文数: 引用数:
h-index:
机构:
Takeuchi, Koji
[1
,2
]
Satoh, Hiroshi
论文数: 0引用数: 0
h-index: 0
机构:
Kyoto Res Ctr Gastrointestinal Dis, Gen Inc Assoc, Kyoto, Japan
Doshisha Womens Coll Liberal Arts, Fac Pharmaceut Sci, Dept Pathophysiol, Kyotanabe, Kyoto, JapanKyoto Pharmaceut Univ, Div Pathol Sci, Dept Pharmacol & Expt Therapeut, Yamashina Ku, Misasagi, Japan
Satoh, Hiroshi
[2
,3
]
机构:
[1] Kyoto Pharmaceut Univ, Div Pathol Sci, Dept Pharmacol & Expt Therapeut, Yamashina Ku, Misasagi, Japan
[2] Kyoto Res Ctr Gastrointestinal Dis, Gen Inc Assoc, Kyoto, Japan
[3] Doshisha Womens Coll Liberal Arts, Fac Pharmaceut Sci, Dept Pathophysiol, Kyotanabe, Kyoto, Japan
Background/Aims: NSAID-induced enteropathy has been the focus of recent basic and clinical research subsequent to the development of the capsule endoscope and double-balloon endoscope. We review the possible pathogenic mechanisms underlying NSAID-induced enteropathy and discuss the role of the inhibition of COX-1/COX-2 and the influences of food as well as various prophylactic treatments on these lesions. Methods: Studies were performed in experimental animals. Results: Multiple factors, such as intestinal hypermotility, decreased mucus secretion, enterobacteria, and upregulation of iNOS/NO expression, are involved in the pathogenesis of NSAID-induced enteropathy, in addition to the decreased production of PGs due to the inhibition of COX. Enterobacterial invasion is the most important pathogenic event, and intestinal hypermotility, which was associated with this event, is essential for the development of these lesions. NSAIDs also upregulate the expression of COX2, and the inhibition of both COX-1 and COX-2 is required for the intestinal ulcerogenic properties of NSAIDs to manifest. NSAID-induced enteropathy is prevented by PGE 2, atropine, ampicillin, and aminoguanidine as well as soluble dietary fiber, and exacerbated by antisecretory drugs such as proton pump inhibitors. Conclusion: These findings on the pathogenesis of NSAID-induced enteropathy will be useful for the future development of intestinal-sparing alternatives to standard NSAIDs. (C) 2015 S. Karger AG, Basel